Tissue | Expression Dynamics | Abbreviation |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0034655110 | Esophagus | ESCC | nucleobase-containing compound catabolic process | 272/8552 | 407/18723 | 2.92e-18 | 2.90e-16 | 272 |
GO:004670018 | Esophagus | ESCC | heterocycle catabolic process | 286/8552 | 445/18723 | 1.12e-15 | 7.47e-14 | 286 |
GO:004427019 | Esophagus | ESCC | cellular nitrogen compound catabolic process | 288/8552 | 451/18723 | 3.03e-15 | 1.79e-13 | 288 |
GO:001943918 | Esophagus | ESCC | aromatic compound catabolic process | 295/8552 | 467/18723 | 1.09e-14 | 5.98e-13 | 295 |
GO:190136118 | Esophagus | ESCC | organic cyclic compound catabolic process | 307/8552 | 495/18723 | 9.99e-14 | 4.80e-12 | 307 |
GO:19016574 | Esophagus | ESCC | glycosyl compound metabolic process | 57/8552 | 88/18723 | 2.32e-04 | 1.44e-03 | 57 |
GO:00725273 | Esophagus | ESCC | pyrimidine-containing compound metabolic process | 52/8552 | 82/18723 | 9.03e-04 | 4.61e-03 | 52 |
GO:19011362 | Esophagus | ESCC | carbohydrate derivative catabolic process | 99/8552 | 172/18723 | 1.11e-03 | 5.54e-03 | 99 |
GO:00442827 | Esophagus | ESCC | small molecule catabolic process | 201/8552 | 376/18723 | 1.35e-03 | 6.41e-03 | 201 |
GO:00091163 | Esophagus | ESCC | nucleoside metabolic process | 39/8552 | 62/18723 | 4.68e-03 | 1.82e-02 | 39 |
GO:0006304 | Esophagus | ESCC | DNA modification | 68/8552 | 120/18723 | 9.95e-03 | 3.42e-02 | 68 |
GO:003465517 | Oral cavity | OSCC | nucleobase-containing compound catabolic process | 244/7305 | 407/18723 | 5.38e-18 | 5.49e-16 | 244 |
GO:004670015 | Oral cavity | OSCC | heterocycle catabolic process | 254/7305 | 445/18723 | 5.07e-15 | 3.31e-13 | 254 |
GO:004427016 | Oral cavity | OSCC | cellular nitrogen compound catabolic process | 256/7305 | 451/18723 | 9.67e-15 | 5.88e-13 | 256 |
GO:001943915 | Oral cavity | OSCC | aromatic compound catabolic process | 263/7305 | 467/18723 | 1.49e-14 | 8.84e-13 | 263 |
GO:190136115 | Oral cavity | OSCC | organic cyclic compound catabolic process | 272/7305 | 495/18723 | 2.73e-13 | 1.36e-11 | 272 |
GO:19016573 | Oral cavity | OSCC | glycosyl compound metabolic process | 52/7305 | 88/18723 | 1.06e-04 | 7.84e-04 | 52 |
GO:19011361 | Oral cavity | OSCC | carbohydrate derivative catabolic process | 89/7305 | 172/18723 | 4.52e-04 | 2.73e-03 | 89 |
GO:00091162 | Oral cavity | OSCC | nucleoside metabolic process | 37/7305 | 62/18723 | 7.79e-04 | 4.23e-03 | 37 |
GO:00442826 | Oral cavity | OSCC | small molecule catabolic process | 174/7305 | 376/18723 | 2.25e-03 | 1.00e-02 | 174 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CDADC1 | SNV | Missense_Mutation | novel | c.539N>C | p.Leu180Ser | p.L180S | Q9BWV3 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CDADC1 | SNV | Missense_Mutation | | c.832N>A | p.Asp278Asn | p.D278N | Q9BWV3 | protein_coding | tolerated(0.26) | benign(0.003) | TCGA-BK-A139-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
CDADC1 | SNV | Missense_Mutation | novel | c.1052G>T | p.Arg351Ile | p.R351I | Q9BWV3 | protein_coding | tolerated_low_confidence(0.21) | benign(0.111) | TCGA-BK-A6W3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CDADC1 | SNV | Missense_Mutation | | c.605T>C | p.Phe202Ser | p.F202S | Q9BWV3 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
CDADC1 | SNV | Missense_Mutation | rs149569821 | c.1534G>A | p.Gly512Arg | p.G512R | Q9BWV3 | protein_coding | deleterious_low_confidence(0.03) | benign(0.181) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
CDADC1 | SNV | Missense_Mutation | novel | c.767N>C | p.Met256Thr | p.M256T | Q9BWV3 | protein_coding | tolerated(0.33) | benign(0.005) | TCGA-D1-A175-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
CDADC1 | SNV | Missense_Mutation | novel | c.1135N>A | p.Pro379Thr | p.P379T | Q9BWV3 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D1-A1NZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CDADC1 | SNV | Missense_Mutation | rs772280432 | c.443G>A | p.Arg148Gln | p.R148Q | Q9BWV3 | protein_coding | tolerated(0.24) | possibly_damaging(0.576) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CDADC1 | SNV | Missense_Mutation | novel | c.1487N>A | p.Pro496His | p.P496H | Q9BWV3 | protein_coding | tolerated_low_confidence(0.14) | benign(0.085) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CDADC1 | SNV | Missense_Mutation | | c.202N>T | p.Pro68Ser | p.P68S | Q9BWV3 | protein_coding | tolerated_low_confidence(0.73) | benign(0.022) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |